目的 分析評(píng)價(jià)童康片單用及聯(lián)合化學(xué)藥治療兒童反復(fù)呼吸道感染的臨床療效及安全性。方法 使用計(jì)算機(jī)對(duì)中英文數(shù)據(jù)庫(kù)，包括中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、維普中文期刊全文數(shù)據(jù)庫(kù)（VIP）、萬方數(shù)據(jù)庫(kù)（Wanfang Data）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（CBM）、Cochrane Library、PubMed和Web of Science進(jìn)行文獻(xiàn)檢索，收集各數(shù)據(jù)庫(kù)建庫(kù)起至2022年12月2日童康片單用及聯(lián)合化學(xué)藥治療兒童反復(fù)呼吸道感染的臨床隨機(jī)對(duì)照試驗(yàn)（RCT），使用RevMan 5.4軟件進(jìn)行Meta分析。結(jié)果 共納入13項(xiàng)RCTs、包括1 411例患兒。Meta分析結(jié)果顯示：試驗(yàn)組總有效率高于對(duì)照組［RR＝1.25，95% CI（1.19，1.31），P＜0.000 01］，且童康片單用及聯(lián)合化學(xué)藥的差異沒有統(tǒng)計(jì)學(xué)意義；治療后兩組免疫球蛋白IgA［MD＝-0.05，95% CI（-0.48，0.37），P＝0.80］、IgG［MD＝-0.16，95% CI（-0.95，0.62），P＝0.68］、IgM［MD＝0.02，95% CI（-0.32，0.37），P＝0.90］、不良反應(yīng)率［RR＝0.80，95% CI（0.23，2.80），P＝0.73］比較，差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 童康片可提高治療兒童反復(fù)呼吸道感染的療效，且單用或聯(lián)合化學(xué)藥對(duì)其有效率影響不大，對(duì)IgA、IgG、IgM及不良反應(yīng)發(fā)生情況沒有明顯影響。

Objective To analyze and evaluate the clinical efficacy and safety of Tongkang Tablets alone and in combination with chemical drugs in the treatment of recurrent respiratory tract infections in children. Methods Data were electronically searched from CNKI, CBM, VIP, Wanfang Database, Cochrane Library, PubMed and Web of Science, from the date of establishment to December 2, 2022, for the randomized controlled trial (RCT) of Tongkang Tablets alone and in combination with chemical drugs in the treatment of recurrent respiratory tract infections in children, and analyzed the data using RevMan 5.4 software. Results A total of 13 RCTs involving 1 411 children were included. The Meta-analysis results showed that the total effective rate of the experimental group was higher than that of the control group [RR = 1.25, 95%CI (1.19, 1.31), P< 0.000 01], and the difference between Tongkang Tablets alone and combined chemical drugs was not statistically significant. After treatment, the two groups of immunoglobulins IgA [MD = -0.05, 95%CI (-0.48, 0.37), P= 0.80], IgG [MD = -0.16, 95%CI (-0.95, 0.62), P= 0.68], IgM [MD = 0.02, 95%CI (-0.32, 0.37), P= 0.90], adverse reaction rate [RR = 0.80, 95%CI (0.23, 2.80), P= 0.73] were compared, the difference was not statistically significant. Conclusion Tongkang Tablets can improve the efficacy of treating recurrent respiratory tract infections in children, and the efficacy of single or combined chemical drugs has little effect, and there is no significant effect on the occurrence of IgA, IgG, IgM and adverse reactions.

R287.5;R969.3

國(guó)家自然科學(xué)青年基金資助項(xiàng)目（82004422）